Shire completes SLI 381 Phase III

Shire (LSE:SHP; SHPGY) said it completed Phase III studies of SLI 381, a once-daily formulation of its marketed Adderall mixed salts of a single-entity amphetamine, to treat Attention Deficit Hyperact...